Provided by Tiger Trade Technology Pte. Ltd.

Virtus LifeSci Biotech Clinical Trials ETF

55.66
-0.1000-0.18%
Volume:12.76K
Turnover:704.50K
Market Cap:52.88M
PE:- -
High:55.66
Open:55.63
Low:54.67
Close:55.76
52wk High:56.18
52wk Low:22.43
Shares:950.00K
Float Shares:950.00K
Volume Ratio:0.57
T/O Rate:1.34%
Dividend:0.65
Dividend Rate:1.17%
ROE:--
ROA:--
PB:1.20
PE(LYR):- -

Loading ...

Glacial Melt Swells Rivers, Himalayan Floods Trigger Landslide on China-Nepal Border

Deep News
·
Yesterday

Nxera to Book US$10m Milestone as FDA Clears Phase 2 Alzheimer’s Drug

TIPRANKS
·
Yesterday

Global Average Sea Surface Temperature Reaches Unprecedented High, Potentially Warmest Since the Last Interglacial Period

Deep News
·
Aug 25

Savara announces presentations of Results from Phase 3 trial of Molgramostim

TIPRANKS
·
Aug 25

Amgen Extends MariTide Study In Obesity And Diabetes, Keeping Investor Focus On Long-Term Potential

TIPRANKS
·
Aug 25

Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial

TIPRANKS
·
Aug 22

AbbVie’s Emraclidine Schizophrenia Study Ends Early: What Investors Need to Know Now

TIPRANKS
·
Aug 22

Bayer’s Adempas Trial Update: What a Terminated Heart-Lung Study Means for BAYRY

TIPRANKS
·
Aug 21

TheraCryf raises £1.05m to advance addiction drug towards Phase 1 trials

TIPRANKS
·
Aug 20

Moderna Stock (MRNA) Soars 133%; Five-Star William Blair Analyst Says Strong Cancer Data Could Be a Game-Changer

TIPRANKS
·
Aug 20

Cullinan, Taiho say results of Phase 3 trial selected for presentation

TIPRANKS
·
Aug 20

Biodexa recruits 87 of 168 subjects in Serenta Phase 3 eRapa polyposis trial

TIPRANKS
·
Aug 19

Video: Moderna skyrockets after cancer vaccine shows promise in Phase 3 trial

TIPRANKS
·
Aug 19

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

GlobeNewswire
·
Aug 19

Patent Cliffs Drive Pharma Expansion as Biotech M&A and IPO Markets Stage a Comeback

Stock News
·
Aug 19

Vivoryon Sets Date for 2026 AGM as Kidney Disease Program Advances

TIPRANKS
·
Aug 19

Amylyx announces Lucidity Phase 3 trial met primary endpoint

TIPRANKS
·
Aug 18

argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM

TIPRANKS
·
Aug 17

Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial

TIPRANKS
·
Aug 17

Mesoblast Reaches Pivotal Phase 3 Milestone in Chronic Back Pain Trial

TIPRANKS
·
Aug 17